Dianabol Cycle Pharma TRT
**Potential Side_Effect Profile of Steroids (Glucocorticoids & Androgenic Steroids)**
| Category | Commonly Reported Adverse Effects | Key Risk Factors | Practical Mitigation Strategies |
|----------|----------------------------------|------------------|---------------------------------|
| **Metabolic** | Hyperglycaemia, weight gain, dyslipidaemia (_ LDL/_ HDL) | Diabetes mellitus, obesity, pre_diabetes | _ Baseline HbA1c & lipid panel
_ Tight glycaemic control; consider dose_reduction or alternate agents if hyperglycaemia occurs |
| **Endocrine** | Hypothalamic_pituitary_adrenal (HPA) axis suppression, osteoporosis, amenorrhoea/menstrual irregularities | Long_term use (>3_months), high doses >20_mg/day prednisone equivalent | _ Periodic bone density scans; calcium/vitamin D supplementation
_ Monitor adrenal function if tapering or abrupt cessation |
| **Immunologic** | Increased infection risk (bacterial, viral) | Patients with chronic immunosuppression or comorbidities | _ Vaccination status review; prophylactic measures; early evaluation of febrile illnesses |
| **Metabolic** | Hyperglycaemia, weight gain, hypertension, dyslipidaemia | Diabetes mellitus or metabolic syndrome | _ Routine fasting glucose/ HbA1c monitoring
_ Blood pressure and lipid profile checks |
| **Psychiatric** | Mood swings, anxiety, insomnia, psychosis | Pre_existing psychiatric disorders | _ Psychiatric screening at baseline; ongoing assessment |
---
## 2. Clinical Monitoring & Follow_Up Plan
| Time after initiation | Assessment | Frequency | Target/Thresholds |
|-----------------------|------------|-----------|-------------------|
| **Baseline (Day_0)** | Full medical history, physical exam, vitals, weight, BMI, CBC, CMP, fasting glucose/HbA1c, lipid panel, BP. Baseline mood and sleep questionnaires. | 1 visit | Baseline values |
| **Week_2** | Vitals, weight, review of side effects (nausea, abdominal pain, constipation), medication adherence, mood/sleep survey. | 1 visit | Detect early GI or psychiatric symptoms; adjust dose if needed |
| **Month_1** | Repeat vitals, weight, BP, fasting glucose/HbA1c, lipid panel, CBC, CMP, review of side effects, dose titration to therapeutic range (if not already). | 1 visit | Adjust dose based on tolerability and efficacy; monitor labs |
| **Months_3_12** | Every 2_3 months: vitals, weight, BP, fasting glucose/HbA1c, lipid panel. Labs (CBC, CMP) every 6 months. Review side effects, adherence. | 1 visit each interval | Early detection of metabolic changes; catch emergent side effects |
| **Adverse Event Monitoring** | Patients instructed to report new symptoms: fatigue, dizziness, nausea, vomiting, weight loss/gain, sexual dysfunction, visual changes. | As needed | Prompt assessment and management (dose adjustment, discontinuation) |
#### 4.3 Early Detection of Metabolic Changes
- **Weight Gain / BMI Increase**: Monitor at each visit; if _5% increase in body weight or BMI >30 kg/m
